Metabolomic Evidence for a Field Effect in Histologically Normal and Metaplastic Tissues in Patients with Esophageal Adenocarcinoma
Patients with Barrett's esophagus (BO) are at increased risk of developing esophageal adenocarcinoma (EAC). Most Barrett's patients, however, do not develop EAC, and there is a need for markers that can identify those most at risk. This study aimed to see if a metabolic signature associate...
Saved in:
| Published in: | Neoplasia (New York, N.Y.) Vol. 19; no. 3; pp. 165 - 174 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Elsevier Inc
01.03.2017
Elsevier |
| Subjects: | |
| ISSN: | 1476-5586, 1522-8002, 1476-5586 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Patients with Barrett's esophagus (BO) are at increased risk of developing esophageal adenocarcinoma (EAC). Most Barrett's patients, however, do not develop EAC, and there is a need for markers that can identify those most at risk. This study aimed to see if a metabolic signature associated with the development of EAC existed. For this, tissue extracts from patients with EAC, BO, and normal esophagus were analyzed using 1H nuclear magnetic resonance. Where possible, adjacent histologically normal tissues were sampled in those with EAC and BO. The study included 46 patients with EAC, 7 patients with BO, and 68 controls who underwent endoscopy for dyspeptic symptoms with normal appearances. Within the cancer cohort, 9 patients had nonneoplastic Barrett's adjacent to the cancer suitable for biopsy. It was possible to distinguish between histologically normal, BO, and EAC tissue in EAC patients [area under the receiver operator curve (AUROC) 1.00, 0.86, and 0.91] and between histologically benign BO in the presence and absence of EAC (AUROC 0.79). In both these cases, sample numbers limited the power of the models. Comparison of histologically normal tissue proximal to EAC versus that from controls (AUROC 1.00) suggests a strong field effect which may develop prior to overt EAC and hence be useful for identifying patients at high risk of developing EAC. Excellent sensitivity and specificity were found for this model to distinguish histologically normal squamous esophageal mucosa in EAC patients and healthy controls, with 8 metabolites being very significantly altered. This may have potential diagnostic value if a molecular signature can detect tissue from which neoplasms subsequently arise. |
|---|---|
| AbstractList | Patients with Barrett's esophagus (BO) are at increased risk of developing esophageal adenocarcinoma (EAC). Most Barrett's patients, however, do not develop EAC, and there is a need for markers that can identify those most at risk. This study aimed to see if a metabolic signature associated with the development of EAC existed. For this, tissue extracts from patients with EAC, BO, and normal esophagus were analyzed using super(1) H nuclear magnetic resonance. Where possible, adjacent histologically normal tissues were sampled in those with EAC and BO. The study included 46 patients with EAC, 7 patients with BO, and 68 controls who underwent endoscopy for dyspeptic symptoms with normal appearances. Within the cancer cohort, 9 patients had nonneoplastic Barrett's adjacent to the cancer suitable for biopsy. It was possible to distinguish between histologically normal, BO, and EAC tissue in EAC patients [area under the receiver operator curve (AUROC) 1.00, 0.86, and 0.91] and between histologically benign BO in the presence and absence of EAC (AUROC 0.79). In both these cases, sample numbers limited the power of the models. Comparison of histologically normal tissue proximal to EAC versus that from controls (AUROC 1.00) suggests a strong field effect which may develop prior to overt EAC and hence be useful for identifying patients at high risk of developing EAC. Excellent sensitivity and specificity were found for this model to distinguish histologically normal squamous esophageal mucosa in EAC patients and healthy controls, with 8 metabolites being very significantly altered. This may have potential diagnostic value if a molecular signature can detect tissue from which neoplasms subsequently arise. Abstract Patients with Barrett's esophagus (BO) are at increased risk of developing esophageal adenocarcinoma (EAC). Most Barrett's patients, however, do not develop EAC, and there is a need for markers that can identify those most at risk. This study aimed to see if a metabolic signature associated with the development of EAC existed. For this, tissue extracts from patients with EAC, BO, and normal esophagus were analyzed using1 H nuclear magnetic resonance. Where possible, adjacent histologically normal tissues were sampled in those with EAC and BO. The study included 46 patients with EAC, 7 patients with BO, and 68 controls who underwent endoscopy for dyspeptic symptoms with normal appearances. Within the cancer cohort, 9 patients had nonneoplastic Barrett's adjacent to the cancer suitable for biopsy. It was possible to distinguish between histologically normal, BO, and EAC tissue in EAC patients [area under the receiver operator curve (AUROC) 1.00, 0.86, and 0.91] and between histologically benign BO in the presence and absence of EAC (AUROC 0.79). In both these cases, sample numbers limited the power of the models. Comparison of histologically normal tissue proximal to EAC versus that from controls (AUROC 1.00) suggests a strong field effect which may develop prior to overt EAC and hence be useful for identifying patients at high risk of developing EAC. Excellent sensitivity and specificity were found for this model to distinguish histologically normal squamous esophageal mucosa in EAC patients and healthy controls, with 8 metabolites being very significantly altered. This may have potential diagnostic value if a molecular signature can detect tissue from which neoplasms subsequently arise. Patients with Barrett's esophagus (BO) are at increased risk of developing esophageal adenocarcinoma (EAC). Most Barrett's patients, however, do not develop EAC, and there is a need for markers that can identify those most at risk. This study aimed to see if a metabolic signature associated with the development of EAC existed. For this, tissue extracts from patients with EAC, BO, and normal esophagus were analyzed using H nuclear magnetic resonance. Where possible, adjacent histologically normal tissues were sampled in those with EAC and BO. The study included 46 patients with EAC, 7 patients with BO, and 68 controls who underwent endoscopy for dyspeptic symptoms with normal appearances. Within the cancer cohort, 9 patients had nonneoplastic Barrett's adjacent to the cancer suitable for biopsy. It was possible to distinguish between histologically normal, BO, and EAC tissue in EAC patients [area under the receiver operator curve (AUROC) 1.00, 0.86, and 0.91] and between histologically benign BO in the presence and absence of EAC (AUROC 0.79). In both these cases, sample numbers limited the power of the models. Comparison of histologically normal tissue proximal to EAC versus that from controls (AUROC 1.00) suggests a strong field effect which may develop prior to overt EAC and hence be useful for identifying patients at high risk of developing EAC. Excellent sensitivity and specificity were found for this model to distinguish histologically normal squamous esophageal mucosa in EAC patients and healthy controls, with 8 metabolites being very significantly altered. This may have potential diagnostic value if a molecular signature can detect tissue from which neoplasms subsequently arise. Patients with Barrett's esophagus (BO) are at increased risk of developing esophageal adenocarcinoma (EAC). Most Barrett's patients, however, do not develop EAC, and there is a need for markers that can identify those most at risk. This study aimed to see if a metabolic signature associated with the development of EAC existed. For this, tissue extracts from patients with EAC, BO, and normal esophagus were analyzed using 1H nuclear magnetic resonance. Where possible, adjacent histologically normal tissues were sampled in those with EAC and BO. The study included 46 patients with EAC, 7 patients with BO, and 68 controls who underwent endoscopy for dyspeptic symptoms with normal appearances. Within the cancer cohort, 9 patients had nonneoplastic Barrett's adjacent to the cancer suitable for biopsy. It was possible to distinguish between histologically normal, BO, and EAC tissue in EAC patients [area under the receiver operator curve (AUROC) 1.00, 0.86, and 0.91] and between histologically benign BO in the presence and absence of EAC (AUROC 0.79). In both these cases, sample numbers limited the power of the models. Comparison of histologically normal tissue proximal to EAC versus that from controls (AUROC 1.00) suggests a strong field effect which may develop prior to overt EAC and hence be useful for identifying patients at high risk of developing EAC. Excellent sensitivity and specificity were found for this model to distinguish histologically normal squamous esophageal mucosa in EAC patients and healthy controls, with 8 metabolites being very significantly altered. This may have potential diagnostic value if a molecular signature can detect tissue from which neoplasms subsequently arise. Patients with Barrett's esophagus (BO) are at increased risk of developing esophageal adenocarcinoma (EAC). Most Barrett's patients, however, do not develop EAC, and there is a need for markers that can identify those most at risk. This study aimed to see if a metabolic signature associated with the development of EAC existed. For this, tissue extracts from patients with EAC, BO, and normal esophagus were analyzed using 1H nuclear magnetic resonance. Where possible, adjacent histologically normal tissues were sampled in those with EAC and BO. The study included 46 patients with EAC, 7 patients with BO, and 68 controls who underwent endoscopy for dyspeptic symptoms with normal appearances. Within the cancer cohort, 9 patients had nonneoplastic Barrett's adjacent to the cancer suitable for biopsy. It was possible to distinguish between histologically normal, BO, and EAC tissue in EAC patients [area under the receiver operator curve (AUROC) 1.00, 0.86, and 0.91] and between histologically benign BO in the presence and absence of EAC (AUROC 0.79). In both these cases, sample numbers limited the power of the models. Comparison of histologically normal tissue proximal to EAC versus that from controls (AUROC 1.00) suggests a strong field effect which may develop prior to overt EAC and hence be useful for identifying patients at high risk of developing EAC. Excellent sensitivity and specificity were found for this model to distinguish histologically normal squamous esophageal mucosa in EAC patients and healthy controls, with 8 metabolites being very significantly altered. This may have potential diagnostic value if a molecular signature can detect tissue from which neoplasms subsequently arise.Patients with Barrett's esophagus (BO) are at increased risk of developing esophageal adenocarcinoma (EAC). Most Barrett's patients, however, do not develop EAC, and there is a need for markers that can identify those most at risk. This study aimed to see if a metabolic signature associated with the development of EAC existed. For this, tissue extracts from patients with EAC, BO, and normal esophagus were analyzed using 1H nuclear magnetic resonance. Where possible, adjacent histologically normal tissues were sampled in those with EAC and BO. The study included 46 patients with EAC, 7 patients with BO, and 68 controls who underwent endoscopy for dyspeptic symptoms with normal appearances. Within the cancer cohort, 9 patients had nonneoplastic Barrett's adjacent to the cancer suitable for biopsy. It was possible to distinguish between histologically normal, BO, and EAC tissue in EAC patients [area under the receiver operator curve (AUROC) 1.00, 0.86, and 0.91] and between histologically benign BO in the presence and absence of EAC (AUROC 0.79). In both these cases, sample numbers limited the power of the models. Comparison of histologically normal tissue proximal to EAC versus that from controls (AUROC 1.00) suggests a strong field effect which may develop prior to overt EAC and hence be useful for identifying patients at high risk of developing EAC. Excellent sensitivity and specificity were found for this model to distinguish histologically normal squamous esophageal mucosa in EAC patients and healthy controls, with 8 metabolites being very significantly altered. This may have potential diagnostic value if a molecular signature can detect tissue from which neoplasms subsequently arise. |
| Author | Ludwig, Christian Singhal, Rishi Ward, Douglas G. Reed, Michelle A.C. Günther, Ulrich L. Carrigan, John B. Taniere, Phillipe Alderson, Derek |
| Author_xml | – sequence: 1 givenname: Michelle A.C. surname: Reed fullname: Reed, Michelle A.C. organization: Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK – sequence: 2 givenname: Rishi surname: Singhal fullname: Singhal, Rishi organization: Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK – sequence: 3 givenname: Christian surname: Ludwig fullname: Ludwig, Christian organization: Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK – sequence: 4 givenname: John B. surname: Carrigan fullname: Carrigan, John B. organization: Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK – sequence: 5 givenname: Douglas G. surname: Ward fullname: Ward, Douglas G. organization: Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK – sequence: 6 givenname: Phillipe surname: Taniere fullname: Taniere, Phillipe organization: Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK – sequence: 7 givenname: Derek surname: Alderson fullname: Alderson, Derek organization: Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK – sequence: 8 givenname: Ulrich L. surname: Günther fullname: Günther, Ulrich L. email: u.l.gunther@bham.ac.uk organization: Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28152423$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkt1rFDEUxQep2A_9A3yRPPqya-5kMplFEErZ2kL9AOtzuJPc2WbNTNZkttJn_3Ez3VqkYPUpIZzfyU3OOSz2hjBQUbwEPgcO9Zv1fKAwL_N2DjDnXDwpDqBS9UzKpt77Y79fHKa05lkISj0r9ssGZFmV4qD4-YFGbIMPvTNsee0sDYZYFyJDdurIW7bsOjIjcwM7c2nMypUz6P0N-xhij57hYNlksvGYxmxy6VLaUpqAzzg6GsbEfrjxii1T2FzhijJznK8JBqNxQ-jxefG0Q5_oxd16VHw9XV6enM0uPr0_Pzm-mBkJUswWaElVmKcBK1rRYo22aeSCiw5VZa1pukoJJXlpsObYNeUig6YtOSkUdSmOivOdrw241pvoeow3OqDTtwchrjTG_ARPGmRbVW3bdFRTRaZtOXWNbC1UFSi0k9frndcmhu_5uaPuXTLkPeZItklDs4BGyTzNf0hrKaHhYnJ9dSfdtj3Z-xl_55UFsBOYGFKK1N1LgOupE3qts6ueOqEBdO5EZtQDxrgxJxOGMaLzj5JvdyTlVK4dRZ2MmwpiXcydyN_mHqXfPaCNd8NUnm90Q2kdtnHIcWvQqdRcf5naOpUVasFB3ea1-LvBPy7_BW58-cg |
| CitedBy_id | crossref_primary_10_1038_s41598_018_23177_w crossref_primary_10_3390_genes13091611 crossref_primary_10_1002_anie_201804736 crossref_primary_10_1080_17474124_2020_1700112 crossref_primary_10_3389_fmolb_2025_1426949 crossref_primary_10_1002_nbm_4038 crossref_primary_10_1007_s00432_024_05857_5 crossref_primary_10_1080_10408347_2021_1901646 crossref_primary_10_1002_ange_201804736 crossref_primary_10_14309_ajg_0000000000003367 crossref_primary_10_1002_jcsm_13131 |
| Cites_doi | 10.1016/j.cgh.2015.05.023 10.1007/s00216-013-6774-8 10.4161/cc.9.10.11601 10.1016/j.jprot.2013.01.016 10.1186/1477-7819-10-271 10.1158/0008-5472.CAN-10-1566 10.1016/j.cgh.2007.09.013 10.1016/j.jchromb.2009.07.039 10.1016/S0002-9610(02)01374-0 10.1038/onc.2013.313 10.1016/j.gtc.2015.02.015 10.1186/1471-2105-12-366 10.1016/j.suc.2012.07.008 10.1371/journal.pone.0030181 10.1055/s-0033-1344617 10.1111/febs.13731 10.1056/NEJMoa0808145 10.1139/y59-099 10.7150/jca.6990 10.1016/j.jmr.2009.11.012 10.1002/bmc.1671 10.1053/hupa.2001.23510 10.3748/wjg.v19.i34.5598 10.3748/wjg.v17.i37.4174 10.1186/1471-2105-8-234 10.1159/000430844 10.1016/j.gie.2007.07.019 |
| ContentType | Journal Article |
| Copyright | 2016 The Authors The Authors Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2016 The Authors – notice: The Authors – notice: Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7TO H94 DOA |
| DOI | 10.1016/j.neo.2016.11.003 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts |
| DatabaseTitleList | Oncogenes and Growth Factors Abstracts MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1476-5586 |
| EndPage | 174 |
| ExternalDocumentID | oai_doaj_org_article_15b44bb8fe6e4ecbb0ef85bd14417ad2 28152423 10_1016_j_neo_2016_11_003 S1476558616301762 1_s2_0_S1476558616301762 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: The Bupa Foundation – fundername: COSMOS EU grantid: FP7-INFRASTRUCTURES-2012-1-312941 – fundername: Wellcome Trust |
| GroupedDBID | --- .1- .FO 0R~ 123 1P~ 29M 2WC 36B 4.4 457 53G AAEDT AAEDW AAIKJ AALRI AAXUO AAYWO ABDBF ABFRF ABMAC ACGFO ACGFS ACPRK ACUHS ACVFH ADBBV ADCNI ADEZE ADVLN AEFWE AENEX AEUPX AEVXI AEXQZ AFJKZ AFPUW AFRHN AFTJW AGHFR AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS APXCP BAWUL BCNDV CAG COF CS3 DIK DU5 E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX F5P FDB GROUPED_DOAJ GX1 HYE IPNFZ IXB KQ8 OC~ OK1 OO- OVT P2P RIG RNS ROL RPM SSZ SV3 UNMZH W2D WOQ Z5R 0SF 6I. AACTN AAFTH AFCTW M~E NCXOZ AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7TO H94 |
| ID | FETCH-LOGICAL-c5153-9ade74afec1d3b3ba6ad885903fa74ddc8f4737502ca60af829c51cb20e7a3623 |
| IEDL.DBID | DOA |
| ISSN | 1476-5586 1522-8002 |
| IngestDate | Fri Oct 03 12:36:25 EDT 2025 Fri Sep 05 06:29:00 EDT 2025 Thu Sep 04 19:48:12 EDT 2025 Thu Apr 03 06:57:21 EDT 2025 Tue Nov 18 21:58:30 EST 2025 Sat Nov 29 02:38:51 EST 2025 Fri Feb 23 02:30:07 EST 2024 Tue Feb 25 19:56:43 EST 2025 Tue Aug 26 17:10:11 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | ML-PLS-DA NMR HGD EAC AUROC PLS-DA BO PCA partial least squares discriminant analysis nuclear magnetic resonance esophageal adenocarcinoma principle component analysis Barrett's esophagus multilevel partial least squares discriminant analysis area under the receiver operator curve high-grade dysplasia |
| Language | English |
| License | This is an open access article under the CC BY license. Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5153-9ade74afec1d3b3ba6ad885903fa74ddc8f4737502ca60af829c51cb20e7a3623 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://doaj.org/article/15b44bb8fe6e4ecbb0ef85bd14417ad2 |
| PMID | 28152423 |
| PQID | 1865518032 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_15b44bb8fe6e4ecbb0ef85bd14417ad2 proquest_miscellaneous_1891875750 proquest_miscellaneous_1865518032 pubmed_primary_28152423 crossref_primary_10_1016_j_neo_2016_11_003 crossref_citationtrail_10_1016_j_neo_2016_11_003 elsevier_sciencedirect_doi_10_1016_j_neo_2016_11_003 elsevier_clinicalkeyesjournals_1_s2_0_S1476558616301762 elsevier_clinicalkey_doi_10_1016_j_neo_2016_11_003 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-03-01 |
| PublicationDateYYYYMMDD | 2017-03-01 |
| PublicationDate_xml | – month: 03 year: 2017 text: 2017-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Neoplasia (New York, N.Y.) |
| PublicationTitleAlternate | Neoplasia |
| PublicationYear | 2017 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Lekakos, Karidis, Dimitroulis, Tsigris, Kouraklis, Nikiteas (bb0030) 2011; 17 Fasanella, Bista, Staton, Rizvi, Uttam, Zhao, Sepulveda, Brand, McGrath, Liu (bb0055) 2013; 4 Konda, Cherkezyan, Subramanian, Wroblewski, Damania, Becker, Gonzalez, Koons, Goldberg, Ferguson (bb0050) 2013; 45 Yang, Wang, Wang, Liang, Chen, Tang, Chen, Deng (bb0120) 2013; 405 Bligh, Dyer (bb0090) 1959; 37 Zhang, Bowers, Liu, Wei, Gowda, Hammoud, Raftery (bb0075) 2012; 7 Bonuccelli, Whitaker-Menezes, Castello-Cros, Pavlides, Pestell, Fatatis, Witkiewicz, Vander Heiden, Migneco, Chiavarina (bb0130) 2010; 9 Davis, Schiller, Eurich, Sawyer (bb0110) 2012; 10 Wu, Xue, Lu, Deng, Liu, Zeng, Wang, Shen (bb0115) 2009; 877 Parsons, Ludwig, Günther, Viant (bb0100) 2007; 8 Braakhuis, Tabor, Kummer, Leemans, Brakenhoff (bb0040) 2003; 63 Montgomery, Bronner, Goldblum, Greenson, Haber, Hart, Lamps, Lauwers, Lazenby, Lewin (bb0035) 2001; 32 Kaz, Grady, Stachler, Bass (bb0145) 2015; 44 He, Haapa-Paananen, Kaminskyy, Kohonen, Fey, Zhivotovsky, Kallioniemi, Perälä (bb0140) 2014; 33 Zhang (bb0010) 2013; 19 Sanchez-Espiridion, Liang, Ajani, Liang, Ye, Hildebrandt, Gu, Wu (bb0065) 2015; 13 Ikeda, Nishiumi, Shinohara, Yoshie, Hatano, Okuno, Bamba, Fukusaki, Takenawa, Azuma (bb0070) 2012; 26 Singhal, Carrigan, Wei, Taniere, Hejmadi, Forde, Ludwig, Bunch, Griffiths, Johnson (bb0085) 2013; 80 Doran, Falk, Somorjai, Lean, Himmelreich, Philips, Russell, Dolenko, Nikulin, Mountford (bb0080) 2003; 185 Günther (bb0135) 2015; 82 Chai, Brown (bb0045) 2009; 39 Ludwig, Günther (bb0105) 2011; 12 Wheeler, Reed (bb0005) 2012; 92 Rastogi, Puli, El-Serag, Bansal, Wani, Sharma (bb0015) 2008; 67 Shaheen, Sharma, Overholt, Wolfsen, Sampliner, Wang, Galanko, Bronner, Goldblum, Bennett (bb0025) 2009; 360 Meiser, Vazquez (bb0125) 2016 Konda, Ross, Ferguson, Hart, Lin, Naylor, Noffsinger, Posner, Dye, Cislo (bb0020) 2008; 6 Yakoub, Keun, Goldin, Hanna (bb0060) 2010; 70 Savorani, Tomasi, Engelsen (bb0095) 2010; 202 Wheeler (10.1016/j.neo.2016.11.003_bb0005) 2012; 92 Günther (10.1016/j.neo.2016.11.003_bb0135) 2015; 82 Singhal (10.1016/j.neo.2016.11.003_bb0085) 2013; 80 Braakhuis (10.1016/j.neo.2016.11.003_bb0040) 2003; 63 Lekakos (10.1016/j.neo.2016.11.003_bb0030) 2011; 17 Yakoub (10.1016/j.neo.2016.11.003_bb0060) 2010; 70 Bligh (10.1016/j.neo.2016.11.003_bb0090) 1959; 37 Rastogi (10.1016/j.neo.2016.11.003_bb0015) 2008; 67 Shaheen (10.1016/j.neo.2016.11.003_bb0025) 2009; 360 He (10.1016/j.neo.2016.11.003_bb0140) 2014; 33 Davis (10.1016/j.neo.2016.11.003_bb0110) 2012; 10 Meiser (10.1016/j.neo.2016.11.003_bb0125) 2016 Yang (10.1016/j.neo.2016.11.003_bb0120) 2013; 405 Montgomery (10.1016/j.neo.2016.11.003_bb0035) 2001; 32 Konda (10.1016/j.neo.2016.11.003_bb0020) 2008; 6 Konda (10.1016/j.neo.2016.11.003_bb0050) 2013; 45 Savorani (10.1016/j.neo.2016.11.003_bb0095) 2010; 202 Wu (10.1016/j.neo.2016.11.003_bb0115) 2009; 877 Chai (10.1016/j.neo.2016.11.003_bb0045) 2009; 39 Kaz (10.1016/j.neo.2016.11.003_bb0145) 2015; 44 Doran (10.1016/j.neo.2016.11.003_bb0080) 2003; 185 Bonuccelli (10.1016/j.neo.2016.11.003_bb0130) 2010; 9 Ikeda (10.1016/j.neo.2016.11.003_bb0070) 2012; 26 Fasanella (10.1016/j.neo.2016.11.003_bb0055) 2013; 4 Zhang (10.1016/j.neo.2016.11.003_bb0010) 2013; 19 Zhang (10.1016/j.neo.2016.11.003_bb0075) 2012; 7 Ludwig (10.1016/j.neo.2016.11.003_bb0105) 2011; 12 Sanchez-Espiridion (10.1016/j.neo.2016.11.003_bb0065) 2015; 13 Parsons (10.1016/j.neo.2016.11.003_bb0100) 2007; 8 30662832 - Transl Cancer Res. 2017 Aug;6(Suppl 6):S979-S981 |
| References_xml | – volume: 12 start-page: 366 year: 2011 ident: bb0105 article-title: MetaboLab—advanced NMR data processing and analysis for metabolomics publication-title: BMC Bioinformatics – volume: 17 start-page: 4174 year: 2011 end-page: 4183 ident: bb0030 article-title: Barrett's esophagus with high-grade dysplasia: focus on current treatment options publication-title: World J Gastroenterol – volume: 360 start-page: 2277 year: 2009 end-page: 2288 ident: bb0025 article-title: Radiofrequency ablation in Barrett's esophagus with dysplasia publication-title: N Engl J Med – volume: 4 start-page: 626 year: 2013 end-page: 634 ident: bb0055 article-title: Nuclear nano-architecture markers of gastric cardia and upper squamous esophagus detect esophageal cancer “field effect” publication-title: J Cancer – volume: 9 start-page: 1960 year: 2010 end-page: 1971 ident: bb0130 article-title: The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts publication-title: Cell Cycle – volume: 63 start-page: 1727 year: 2003 end-page: 1730 ident: bb0040 article-title: A genetic explanation of Slaughter's concept of field cancerization evidence and clinical implications publication-title: Cancer Res – volume: 877 start-page: 3111 year: 2009 end-page: 3117 ident: bb0115 article-title: Metabolomic study for diagnostic model of oesophageal cancer using gas chromatography/mass spectrometry publication-title: J Chromatogr B Analyt Technol Biomed Life Sci – volume: 44 start-page: 473 year: 2015 end-page: 489 ident: bb0145 article-title: Genetic and epigenetic alterations in barrett's esophagus and esophageal adenocarcinoma publication-title: Gastroenterol Clin North Am – volume: 405 start-page: 3381 year: 2013 end-page: 3389 ident: bb0120 article-title: Study of metabonomic profiles of human esophageal carcinoma by use of high-resolution magic-angle spinning 1H NMR spectroscopy and multivariate data analysis publication-title: Anal Bioanal Chem – volume: 33 start-page: 3538 year: 2014 end-page: 3549 ident: bb0140 article-title: Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis publication-title: Oncogene – volume: 67 start-page: 394 year: 2008 end-page: 398 ident: bb0015 article-title: Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis publication-title: Gastrointest Endosc – volume: 92 start-page: 1077 year: 2012 end-page: 1087 ident: bb0005 article-title: Epidemiology of esophageal cancer publication-title: Surg Clin North Am – volume: 80 start-page: 207 year: 2013 end-page: 215 ident: bb0085 article-title: MALDI profiles of proteins and lipids for the rapid characterisation of upper GI-tract cancers publication-title: J Proteomics – volume: 19 start-page: 5598 year: 2013 ident: bb0010 article-title: Epidemiology of esophageal cancer publication-title: World J Gastroenterol – volume: 32 start-page: 368 year: 2001 end-page: 378 ident: bb0035 article-title: Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation publication-title: Hum Pathol – volume: 37 start-page: 911 year: 1959 end-page: 917 ident: bb0090 article-title: A rapid method of total lipid extraction and purification publication-title: Can J Biochem Physiol – volume: 39 start-page: 331 year: 2009 end-page: 337 ident: bb0045 article-title: Field effect in cancer—an update publication-title: Ann Clin Lab Sci – volume: 8 start-page: 234 year: 2007 ident: bb0100 article-title: Improved classification accuracy in 1- and 2-dimensional NMR metabolomics data using the variance stabilising generalised logarithm transformation publication-title: BMC Bioinformatics – volume: 6 start-page: 159 year: 2008 end-page: 164 ident: bb0020 article-title: Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? publication-title: Clin Gastroenterol Hepatol – volume: 7 start-page: e30181 year: 2012 ident: bb0075 article-title: Esophageal cancer metabolite biomarkers detected by LC-MS and NMR methods publication-title: PLoS One – year: 2016 ident: bb0125 article-title: Give it or take it: the flux of one-carbon in cancer cells publication-title: FEBS J – volume: 26 start-page: 548 year: 2012 end-page: 558 ident: bb0070 article-title: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer publication-title: Biomed Chromatogr – volume: 202 start-page: 190 year: 2010 end-page: 202 ident: bb0095 article-title: icoshift: a versatile tool for the rapid alignment of 1D NMR spectra publication-title: J Magn Reson – volume: 185 start-page: 232 year: 2003 end-page: 238 ident: bb0080 article-title: Pathology of Barrett's esophagus by proton magnetic resonance spectroscopy and a statistical classification strategy publication-title: Am J Surg – volume: 82 start-page: 153 year: 2015 end-page: 165 ident: bb0135 article-title: Metabolomics biomarkers for breast cancer publication-title: Pathobiology – volume: 45 start-page: 983 year: 2013 end-page: 988 ident: bb0050 article-title: Nanoscale markers of esophageal field carcinogenesis: potential implications for esophageal cancer screening publication-title: Endoscopy – volume: 10 start-page: 271 year: 2012 end-page: 283 ident: bb0110 article-title: Urinary metabolomic signature of esophageal cancer and Barrett's esophagus publication-title: World J Surg Oncol – volume: 13 start-page: 1730 year: 2015 end-page: 1737.e9 ident: bb0065 article-title: Identification of serum markers of esophageal adenocarcinoma by global and targeted metabolic profiling publication-title: Clin Gastroenterol Hepatol – volume: 70 start-page: 9129 year: 2010 end-page: 9136 ident: bb0060 article-title: Metabolic profiling detects field effects in nondysplastic tissue from esophageal cancer patients publication-title: Cancer Res – volume: 13 start-page: 1730 year: 2015 ident: 10.1016/j.neo.2016.11.003_bb0065 article-title: Identification of serum markers of esophageal adenocarcinoma by global and targeted metabolic profiling publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2015.05.023 – volume: 405 start-page: 3381 year: 2013 ident: 10.1016/j.neo.2016.11.003_bb0120 article-title: Study of metabonomic profiles of human esophageal carcinoma by use of high-resolution magic-angle spinning 1H NMR spectroscopy and multivariate data analysis publication-title: Anal Bioanal Chem doi: 10.1007/s00216-013-6774-8 – volume: 9 start-page: 1960 year: 2010 ident: 10.1016/j.neo.2016.11.003_bb0130 article-title: The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts publication-title: Cell Cycle doi: 10.4161/cc.9.10.11601 – volume: 80 start-page: 207 year: 2013 ident: 10.1016/j.neo.2016.11.003_bb0085 article-title: MALDI profiles of proteins and lipids for the rapid characterisation of upper GI-tract cancers publication-title: J Proteomics doi: 10.1016/j.jprot.2013.01.016 – volume: 10 start-page: 271 year: 2012 ident: 10.1016/j.neo.2016.11.003_bb0110 article-title: Urinary metabolomic signature of esophageal cancer and Barrett's esophagus publication-title: World J Surg Oncol doi: 10.1186/1477-7819-10-271 – volume: 70 start-page: 9129 year: 2010 ident: 10.1016/j.neo.2016.11.003_bb0060 article-title: Metabolic profiling detects field effects in nondysplastic tissue from esophageal cancer patients publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-1566 – volume: 6 start-page: 159 year: 2008 ident: 10.1016/j.neo.2016.11.003_bb0020 article-title: Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2007.09.013 – volume: 877 start-page: 3111 year: 2009 ident: 10.1016/j.neo.2016.11.003_bb0115 article-title: Metabolomic study for diagnostic model of oesophageal cancer using gas chromatography/mass spectrometry publication-title: J Chromatogr B Analyt Technol Biomed Life Sci doi: 10.1016/j.jchromb.2009.07.039 – volume: 185 start-page: 232 year: 2003 ident: 10.1016/j.neo.2016.11.003_bb0080 article-title: Pathology of Barrett's esophagus by proton magnetic resonance spectroscopy and a statistical classification strategy publication-title: Am J Surg doi: 10.1016/S0002-9610(02)01374-0 – volume: 33 start-page: 3538 year: 2014 ident: 10.1016/j.neo.2016.11.003_bb0140 article-title: Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis publication-title: Oncogene doi: 10.1038/onc.2013.313 – volume: 44 start-page: 473 year: 2015 ident: 10.1016/j.neo.2016.11.003_bb0145 article-title: Genetic and epigenetic alterations in barrett's esophagus and esophageal adenocarcinoma publication-title: Gastroenterol Clin North Am doi: 10.1016/j.gtc.2015.02.015 – volume: 12 start-page: 366 year: 2011 ident: 10.1016/j.neo.2016.11.003_bb0105 article-title: MetaboLab—advanced NMR data processing and analysis for metabolomics publication-title: BMC Bioinformatics doi: 10.1186/1471-2105-12-366 – volume: 92 start-page: 1077 year: 2012 ident: 10.1016/j.neo.2016.11.003_bb0005 article-title: Epidemiology of esophageal cancer publication-title: Surg Clin North Am doi: 10.1016/j.suc.2012.07.008 – volume: 7 start-page: e30181 year: 2012 ident: 10.1016/j.neo.2016.11.003_bb0075 article-title: Esophageal cancer metabolite biomarkers detected by LC-MS and NMR methods publication-title: PLoS One doi: 10.1371/journal.pone.0030181 – volume: 39 start-page: 331 year: 2009 ident: 10.1016/j.neo.2016.11.003_bb0045 article-title: Field effect in cancer—an update publication-title: Ann Clin Lab Sci – volume: 45 start-page: 983 year: 2013 ident: 10.1016/j.neo.2016.11.003_bb0050 article-title: Nanoscale markers of esophageal field carcinogenesis: potential implications for esophageal cancer screening publication-title: Endoscopy doi: 10.1055/s-0033-1344617 – year: 2016 ident: 10.1016/j.neo.2016.11.003_bb0125 article-title: Give it or take it: the flux of one-carbon in cancer cells publication-title: FEBS J doi: 10.1111/febs.13731 – volume: 360 start-page: 2277 year: 2009 ident: 10.1016/j.neo.2016.11.003_bb0025 article-title: Radiofrequency ablation in Barrett's esophagus with dysplasia publication-title: N Engl J Med doi: 10.1056/NEJMoa0808145 – volume: 37 start-page: 911 year: 1959 ident: 10.1016/j.neo.2016.11.003_bb0090 article-title: A rapid method of total lipid extraction and purification publication-title: Can J Biochem Physiol doi: 10.1139/y59-099 – volume: 4 start-page: 626 year: 2013 ident: 10.1016/j.neo.2016.11.003_bb0055 article-title: Nuclear nano-architecture markers of gastric cardia and upper squamous esophagus detect esophageal cancer “field effect” publication-title: J Cancer doi: 10.7150/jca.6990 – volume: 202 start-page: 190 year: 2010 ident: 10.1016/j.neo.2016.11.003_bb0095 article-title: icoshift: a versatile tool for the rapid alignment of 1D NMR spectra publication-title: J Magn Reson doi: 10.1016/j.jmr.2009.11.012 – volume: 26 start-page: 548 year: 2012 ident: 10.1016/j.neo.2016.11.003_bb0070 article-title: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer publication-title: Biomed Chromatogr doi: 10.1002/bmc.1671 – volume: 32 start-page: 368 year: 2001 ident: 10.1016/j.neo.2016.11.003_bb0035 article-title: Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation publication-title: Hum Pathol doi: 10.1053/hupa.2001.23510 – volume: 63 start-page: 1727 year: 2003 ident: 10.1016/j.neo.2016.11.003_bb0040 article-title: A genetic explanation of Slaughter's concept of field cancerization evidence and clinical implications publication-title: Cancer Res – volume: 19 start-page: 5598 year: 2013 ident: 10.1016/j.neo.2016.11.003_bb0010 article-title: Epidemiology of esophageal cancer publication-title: World J Gastroenterol doi: 10.3748/wjg.v19.i34.5598 – volume: 17 start-page: 4174 year: 2011 ident: 10.1016/j.neo.2016.11.003_bb0030 article-title: Barrett's esophagus with high-grade dysplasia: focus on current treatment options publication-title: World J Gastroenterol doi: 10.3748/wjg.v17.i37.4174 – volume: 8 start-page: 234 year: 2007 ident: 10.1016/j.neo.2016.11.003_bb0100 article-title: Improved classification accuracy in 1- and 2-dimensional NMR metabolomics data using the variance stabilising generalised logarithm transformation publication-title: BMC Bioinformatics doi: 10.1186/1471-2105-8-234 – volume: 82 start-page: 153 year: 2015 ident: 10.1016/j.neo.2016.11.003_bb0135 article-title: Metabolomics biomarkers for breast cancer publication-title: Pathobiology doi: 10.1159/000430844 – volume: 67 start-page: 394 year: 2008 ident: 10.1016/j.neo.2016.11.003_bb0015 article-title: Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis publication-title: Gastrointest Endosc doi: 10.1016/j.gie.2007.07.019 – reference: 30662832 - Transl Cancer Res. 2017 Aug;6(Suppl 6):S979-S981 |
| SSID | ssj0016177 |
| Score | 2.2598817 |
| Snippet | Patients with Barrett's esophagus (BO) are at increased risk of developing esophageal adenocarcinoma (EAC). Most Barrett's patients, however, do not develop... Abstract Patients with Barrett's esophagus (BO) are at increased risk of developing esophageal adenocarcinoma (EAC). Most Barrett's patients, however, do not... |
| SourceID | doaj proquest pubmed crossref elsevier |
| SourceType | Open Website Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 165 |
| SubjectTerms | Adenocarcinoma - drug therapy Adenocarcinoma - metabolism Adenocarcinoma - pathology Antineoplastic Agents - therapeutic use Barrett Esophagus - metabolism Barrett Esophagus - pathology Case-Control Studies Esophageal Mucosa - metabolism Esophageal Mucosa - pathology Esophageal Neoplasms - drug therapy Esophageal Neoplasms - metabolism Esophageal Neoplasms - pathology Female Humans Magnetic Resonance Spectroscopy Male Metabolome Metabolomics - methods Metaplasia Oncology |
| Title | Metabolomic Evidence for a Field Effect in Histologically Normal and Metaplastic Tissues in Patients with Esophageal Adenocarcinoma |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1476558616301762 https://www.clinicalkey.es/playcontent/1-s2.0-S1476558616301762 https://dx.doi.org/10.1016/j.neo.2016.11.003 https://www.ncbi.nlm.nih.gov/pubmed/28152423 https://www.proquest.com/docview/1865518032 https://www.proquest.com/docview/1891875750 https://doaj.org/article/15b44bb8fe6e4ecbb0ef85bd14417ad2 |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1476-5586 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0016177 issn: 1476-5586 databaseCode: DOA dateStart: 19990101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LixQxEA66iHgR346PJYInoTWv7iRHlR08uMOCq8wtJOk0jIy9y_SssOf941al04OCzl48zGVIdYWq6qovnXoQ8prVSYjIRSW8bCsVVV2FkHjVRR4sV7z1ubbq22e9WJjl0p78NuoLc8LG9sCj4N7xOigVgulSk1SKIbDUmTq0eBDQvs3eF1DPdJgq9wcQl_NYFaWbqq5NM91n5syuPlf98eYttu-cpmWViJQb9_8RmP4FPHMAmt8jdwtypO_HHd8nN1L_gNw-LnfjD8nVcdqCRtdYZkynYaEUMCn1dI55anTsVExXPc3NQYrXW1_SBQLXNfV9S_Eh54CogQk9zUoZkOBkbL86UPxuS49w9gE4ItwOsIFwuIE9nP3wj8jX-dHpx09VGbFQRQAysrK-TVp54M5bGWTwjW-NqS2TndeqbaPplJaAKkT0DfOdERYIYxAsaQ-xTz4mB_1Zn54Siq82Az1bbb2CnxeNTMl6GwAEBCtnhE1idrH0H8cxGGs3JZp9d6AZh5qBcwk2LZ2RNzuS87H5xr7FH1B3u4XYNzv_AdbkijW566xpRsSkeTeVpoIzhQet9nHWfyNKQ3EHg-NuEI65L2iPaI4AgkFcDbBTO8qCeEYkcx3DV5NROvAGeMXjYckFMMI6Y26YFPvWWI5jDGo2I09Gi94JTRjAc4Cwn_0PYT4ndwSCoJyx94IcbDcX6SW5FX9uV8PmkNzUS3OYX9tfZtpGGA |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Metabolomic+Evidence+for+a+Field+Effect+in+Histologically+Normal+and+Metaplastic+Tissues+in+Patients+with+Esophageal+Adenocarcinoma&rft.jtitle=Neoplasia+%28New+York%2C+N.Y.%29&rft.au=Reed%2C+Michelle+A+C&rft.au=Singhal%2C+Rishi&rft.au=Ludwig%2C+Christian&rft.au=Carrigan%2C+John+B&rft.date=2017-03-01&rft.issn=1476-5586&rft.eissn=1476-5586&rft.volume=19&rft.issue=3&rft.spage=165&rft_id=info:doi/10.1016%2Fj.neo.2016.11.003&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14765586%2FS1476558617X0002X%2Fcov150h.gif |